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Purpose of the study
Etravirine (ETR, TMC125) has shown good in vitro activ-
ity against primary HIV-1 group M isolates from different
subtypes and has demonstrated durable efficacy in treat-
ment-experienced, HIV-1 infected patients in the Phase III
DUET trials. In vivo efficacy and in vitro activity of ETR
against different HIV-1 subtypes were further investigated.
Methods
DUET patients were randomized 1:1 to ETR (200 mg BID)
or placebo, both with a background regimen of NRTIs,
darunavir/ritonavir and optional enfuvirtide. Subgroup
analyses of the effect of HIV-1 subtype on the proportion
of patients with viral load (VL) <50 HIV-1 RNA copies/mL
(TLOVR imputation algorithm) were conducted on
pooled week 48 data. Genotype/subtype and phenotype
determinations were performed using the Virco® TYPE
HIV-1 and Antivirogram™ assays, respectively. The effect
of HIV-1 subtype on ETR fold change in EC50 value (FC)
was analyzed in HIV-1 recombinant clinical isolates from
treatment-naïve patients enrolled in other Tibotec trials (n
= 872) that included 49% of HIV-1 subtype non-B (18%
CRF01_AE; 16% C; 5% A1; 3% CRF12_BF; 2%
CRF02_AG; 1% F1; 3% other).
Summary of results
In DUET, HIV-1 subtype was available for 594 and 595
patients in the ETR and placebo arms, respectively. The
majority of these (93.8%) harboured HIV-1 subtype B.
Among the non-B subtypes, CRF12_BF (2.1%), F1
(1.2%), and CRF02_AG (0.8%) were most prevalent.
Baseline disease characteristics (VL, CD4, ETR FC, DRV
FC, PSS) were similar between patients with different sub-
types, except for a higher number of sensitive NRTIs used
in those with HIV-1 subtype non-B. In the ETR arm, viro-
logical responses at week 48 were 59.9% (336/561) for
HIV-1 subtype B vs. 72.7% (24/33) for all other HIV-1
subtype non-B, as compared to an overall response of
60.6%.
These data were further supported by in vitro results that
indicated a comparable median (IQR) ETR FC in virus iso-
lates from treatment-naïve patients infected with subtype
B or non-B (1.1, 0.8–1.6 or 1.2, 0.8 1.7), respectively.
Conclusion
In the DUET studies, ETR was equally effective in sup-
pressing viral replication in patients infected with HIV-1
subtype B or non-B. Furthermore, both subtype B and
non-B HIV-1 recombinant clinical isolates from treat-
ment-naïve patients exhibited comparable levels of in
vitro phenotypic susceptibility to ETR. These results con-
firmed the broad activity of ETR against HIV-1.
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